OR WAIT null SECS
January 31, 2020
The license gives Daiichi Sankyo access to ERS Genomics’ genome-editing technology for internal R&D initiatives.
Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.
January 28, 2020
The agency has published seven guidance documents directed at the development and manufacture of gene therapies.
January 21, 2020
GE Healthcare Life Sciences’ new facility for cell and gene processing supplies will be open in 2022.
January 16, 2020
The formation of the new gene therapy company stems from the progress and success of Nationwide Children’s Hospital’s clinical manufacturing and gene therapy work.
January 15, 2020
Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.
January 09, 2020
Under the agreement, Almirall will leverage WuXi Biologics’ proprietary WuXiBody platform to develop bispecific antibodies for dermatological diseases.
January 08, 2020
The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.
Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.
December 02, 2019
Applying lessons of raw materials’ characterization and supply-chain control from the semiconductor industry allow more rigorous control of the biopharmaceutical manufacturing process.